Track market-moving stories before they get noisy

A month has gone by since the last earnings report for IPG Photonics (IPGP - Free Report) . Shares have lost about 16.6% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is IPG due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

IPGP Q2 Earnings Beat Estimates on Industrial Solutions GrowthIPG Photonics Corporation reported second-quarter 2026 adjusted earnings of 58 cents per share, up 93% year over year. The figure beat the Zacks Consensus Estimate by 45%.

Revenues of $278.58 million rose 11% year over year but missed the consensus mark by 0.2%. Strong demand across Industrial Solutions, particularly battery manufacturing, supported growth. Emerging growth products represented 58% of revenues, up from 53% in the prior quarter.

IPGP Revenue Mix Tilts Toward Industrial SolutionsIndustrial Solutions revenues increased 16% year over year to $237 million and accounted for 85% of total sales. Growth was driven by higher welding, marking, cleaning and additive manufacturing revenues. Sequentially, the segment advanced 4%, led by welding and cleaning applications.

Battery manufacturing remained an important demand driver for welding products. The performance helped IPGP deliver its third consecutive quarter of double-digit year-over-year revenue growth. Changes in foreign exchange rates added roughly 2% to total revenues.

IPG Photonics Sees Mixed Advanced Solutions TrendsAdvanced Solutions revenues declined 9% year over year to $41.5 million. Lower micromachining and defense sales more than offset growth in semiconductor applications. However, revenues improved 10% sequentially as semiconductor and micromachining demand strengthened.

The company continues to pursue expansion opportunities in higher-growth applications. Its planned acquisition of Lumibird Medical is expected to establish a larger medical laser platform, including ophthalmology treatment and diagnostic systems, while complementing IPG Photonics’ existing urology presence.

IPGP Records Broad Growth Across AsiaAsia revenues increased 19% year over year, primarily reflecting stronger welding sales. The region also posted sequential growth as demand for Industrial Solutions remained robust.

Europe revenues rose 5% from the year-ago quarter, supported by cleaning and additive manufacturing applications. North American sales decreased 2% due to lower cutting, medical and defense revenues, although marking and defense sales improved sequentially.

IPGP Operating DetailsGAAP gross margin increased 310 basis points year over year to 40.4%. Adjusted gross margin expanded 290 basis points to 40.7%. Both measures also improved sharply from the first quarter.

The margin gains reflected lower product costs, reduced inventory provisions and $4.7 million in tariff refunds recorded during the quarter. Operating expenses, excluding foreign exchange and other items, were $91.4 million, up 1% year over year but down 2% sequentially. Expenses benefited from a $1.8 million German research and development tax credit.

Adjusted EBITDA rose 54% to $48.5 million, exceeding the upper end of management’s second-quarter guidance.

Adjusted operating income surged 246% year over year to $23.9 million. 

IPG Photonics Maintains Debt-Free Balance SheetIPG Photonics ended the quarter with $871 million in cash and short-term investments and $33 million in long-term investments. The company had no debt.

For the second quarter of 2026, Cash generated from operations was $37.8 million.

IPGP Issues Q3 Guidance Amid Tariff UncertaintyFor the third quarter of 2026, IPGP expects revenues between $265 million and $295 million. Adjusted gross margin is projected to be in the range of 37.5% to 40.5%, while adjusted operating expenses are expected to be between $92 million and $95 million.

Adjusted earnings are forecasted to be between 30 cents and 60 cents per share. Adjusted EBITDA is expected to be in the range of $35 million-$51 million.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended upward during the past month.

The consensus estimate has shifted 5.58% due to these changes.

VGM ScoresAt this time, IPG has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, IPG has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

IPG Photonics (IPGP - Free Report) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.3 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +45.00%. A quarter ago, it was expected that this high-powered laser maker would post earnings of $0.32 per share when it actually produced earnings of $0.29, delivering a surprise of -9.38%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

IPG, which belongs to the Zacks Lasers Systems and Components industry, posted revenues of $278.58 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.21%. This compares to year-ago revenues of $250.72 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

IPG shares have added about 21.8% since the beginning of the year versus the S&P 500's gain of 11%.

What's Next for IPG?While IPG has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for IPG was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $277.13 million in revenues for the coming quarter and $1.66 on $1.11 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Lasers Systems and Components is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the broader Zacks Computer and Technology sector, Inseego (INSG - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This holding company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of -250%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Inseego's revenues are expected to be $40.1 million, down 0.3% from the year-ago quarter.

 Creates a Scaled Medical Laser Platform, Accelerating IPG’s Strategic Expansion in Advanced Solutions

Expected to Be Accretive to Gross Margin, EBITDA, and Adjusted EPS

MARLBOROUGH, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- IPG Photonics Corporation (NASDAQ: IPGP) today announced that it has entered into a binding offer to acquire Lumibird Medical. The acquisition advances IPG’s strategy, further expanding the Advanced Solutions portfolio in attractive medical markets. The transaction is expected to deliver financial benefits by adding a high-margin business that is accretive to gross margin, EBITDA and adjusted EPS. IPG believes that the combined medical businesses will create a scaled medical laser platform for growth with complementary established leadership in ophthalmology and urology. The company expects that this also adds approximately $1 billion in addressable market for Advanced Solutions, expanding long-term value creation opportunities that leverage IPG’s capabilities.

IPG intends to acquire Lumibird Medical for a purchase price of €300 million on a cash-free, debt-free basis. The purchase price will be paid in cash at closing. A contingent earnout consideration of up to €50 million additional in cash is based on achieving certain 2026 and 2027 performance metrics. The acquisition will be funded with cash on hand.

“We expect that this acquisition will accelerate our strategic expansion in attractive medical markets in Advanced Solutions,” said Dr. Mark Gitin, IPG Photonics’ Chief Executive Officer. “Lumibird Medical’s leadership in ophthalmology complements our strength in urology, which will create a scaled medical platform with opportunities to accelerate innovation, broaden our commercial reach and deliver differentiated solutions for physicians and patients. We expect the transaction to strengthen our long-term growth profile and provide significant value creation. I am looking forward to welcoming the Lumibird Medical team to IPG.”

“I’m excited about the future of Lumibird Medical, which will benefit significantly from IPG’s scale and leadership in lasers, photonics and applications,” said Jean-Marc Gendre, CEO of Lumibird Medical. “I am convinced that becoming part of IPG will provide our teams, our technologies and our customers with outstanding opportunities to accelerate this remarkable journey while preserving the culture of innovation that has made our success.”

Lumibird Medical is a global leader in diagnostic and treatment systems for ophthalmology, a highly regulated medical laser market that is largely driven by non-discretionary spending. The company designs and produces diagnostic and therapeutic tools for conditions including cataracts, glaucoma, dry eye and age-related macular degeneration, and is a partner of choice for specialist and generalist patient care. Its proprietary laser technology delivers innovative solutions, from diagnosis to laser treatment, through market-leading brands including Quantel Medical, Ellex and Optotek Medical. Headquartered in France, the company has three major global facilities and more than 450 employees worldwide. Lumibird Medical has a track record of sales growth and EBITDA margin expansion. For the fiscal year ended December 31, 2025, Lumibird Medical reported revenue of €112.2 million and EBITDA of €24.1 million with EBITDA margin of 21.5%1.

1 Lumibird Medical's historical financials are prepared under IFRS. Please see the reconciliation from IFRS to U.S. GAAP in the appendix of the presentation furnished with the SEC on Form 8-K.

Transaction Timing

Following completion of the information and consultation process with Lumibird Medical's works council in accordance with French law, the parties expect to enter into a definitive purchase agreement. IPG Photonics expects the transaction to close during the fourth quarter of 2026, subject to customary closing conditions.

Conference Call Details

The Company will hold a conference call tomorrow, July 17, 2026, at 8:00 a.m. ET. To access the call, please dial 877-407-6184 in the US or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the Company’s website at investor.ipgphotonics.com.

Contact

Eugene Fedotoff
Senior Director, Investor Relations
IPG Photonics Corporation
508-597-4713
[email protected]

About IPG Photonics Corporation

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what's possible. Discover more at www.ipgphotonics.com.

Safe Harbor Statement

Information and statements provided by IPG and its employees, including statements in this press release, that relate to future plans, events or performance are forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. These statements involve risks and uncertainties. Any statements in this press release that are not statements of historical fact are forward-looking statements, including those statements related to the proposed acquisition of Lumibird Medical (the "Proposed Transaction") and the timing and completion thereof, advancing IPG’s strategy , further expanding the Advanced Solutions portfolio in attractive medical markets, delivering financial benefits by adding a high-margin business, accretive to gross margin, EBITDA and adjusted EPS, the combination creating a scaled platform for growth, adding approximately $1 billion in addressable market, expanding long-term value creation opportunities that leverage IPG’s capabilities, expecting the transaction to provide opportunities to accelerate innovation, broaden commercial reach, deliver differentiated solutions, to strengthen long-term growth profile, provide value creation and to be accretive to margin, EBITDA and adjusted EPS, the ability to complete the information and consultation process with Lumibird Medical's works council, the execution of definitive agreements relating to the Proposed Transaction, the ability to obtain required regulatory approvals and to satisfy other customary closing conditions, the ability to successfully integrate Lumibird Medical's business and retain its employees, customers and distributors, and the realization of anticipated synergies and the expected closing date. Factors that could cause actual results to differ materially include risks and uncertainties, including risks associated with the strength or weakness of business conditions in industries and geographic markets that IPG serves, particularly the effect of downturns in the markets IPG serves; uncertainties and adverse changes in the general economic conditions of markets; inability to manage risks associated with international customers and operations; changes in trade controls and tariff policies; IPG's ability to penetrate new applications for fiber lasers and increase market share; the rate of acceptance and penetration of IPG's products; foreign currency fluctuations; high levels of fixed costs from IPG's vertical integration; the appropriateness of IPG's manufacturing capacity for the level of demand; competitive factors, including declining average selling prices; the effect of acquisitions and investments; inventory write-downs; asset impairment charges; intellectual property infringement claims and litigation; interruption in supply of key components; manufacturing risks; government regulations and trade sanctions; and other risks identified in IPG's SEC filings. There can be no assurance that the Proposed Transaction will be consummated on the anticipated timeline or at all. Readers are encouraged to refer to the risk factors described in IPG's Annual Report on Form 10-K (filed with the SEC on February 23, 2026) and IPG's reports filed with the SEC, as applicable. Actual results, events and performance may differ materially. Readers are cautioned not to rely on the forward-looking statements, which speak only as of the date hereof. IPG undertakes no obligation to update the forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Use of Non-GAAP Adjusted Financial Information

We refer to certain financial measures that are not recognized under United States generally accepted accounting principles (“GAAP”) and are provided as supplemental information to enhance understanding of the Company’s financial performance. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measure presented by the Company.